ID: ALA145118

Max Phase: Preclinical

Molecular Formula: C16H14N6O3

Molecular Weight: 338.33

Molecule Type: Small molecule

Representations

Canonical SMILES:  N/C(=N\O)c1ccc(-c2ccc(-c3ccc(/C(N)=N\O)cn3)o2)nc1

Standard InChI:  InChI=1S/C16H14N6O3/c17-15(21-23)9-1-3-11(19-7-9)13-5-6-14(25-13)12-4-2-10(8-20-12)16(18)22-24/h1-8,23-24H,(H2,17,21)(H2,18,22)

Standard InChI Key:  KNGZDDMFCPNENL-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 338.33

Molecular Weight (Monoisotopic): 338.1127

AlogP: 1.59

#Rotatable Bonds: 4

Polar Surface Area: 156.14

Molecular Species: BASE

HBA: 7

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.00

CX Basic pKa: 13.62

CX LogP: 0.42

CX LogD: 0.42

Aromatic Rings: 3

Heavy Atoms: 25

QED Weighted: 0.24

Np Likeness Score: -0.67

References

1. Ismail MA, Brun R, Easterbrook JD, Tanious FA, Wilson WD, Boykin DW..  (2003)  Synthesis and antiprotozoal activity of aza-analogues of furamidine.,  46  (22): [PMID:14561095] [10.1021/jm0302602]

2. Wenzler T, Boykin DW, Ismail MA, Hall JE, Tidwell RR, Brun R..  (2009)  New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289.,  53  (10): [PMID:19620327] [10.1128/aac.00225-09]

3. Generaux CN, Ainslie GR, Bridges AS, Ismail MA, Boykin DW, Tidwell RR, Thakker DR, Paine MF..  (2013)  Compartmental and enzyme kinetic modeling to elucidate the biotransformation pathway of a centrally acting antitrypanosomal prodrug.,  41  (2): [PMID:23223498] [10.1124/dmd.112.048231]

Source

Source(1):

• Scientific Literature